Defective expression of ataxia telangiectasia mutated (ATM) as a cause of p53 dysfunction in B-cell chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Pettitt, AR
Stankovic, T
Sherrington, PD
Stewart, GS
Cawley, JC
Taylor, AM
机构：
[1] Univ Liverpool, Dept Haematol, Liverpool L69 3BX, Merseyside, England
[2] Univ Birmingham, Inst Canc Studies, CRC, Birmingham B15 2TT, W Midlands, England
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2192
引用
收藏
页码：490A / 490A
页数：1
相关论文
共 50 条
  • [41] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52
  • [42] UCN-O1: A promising new agent for B-cell chronic lymphocytic leukemia (B-CLL) that induces apoptosis independent of p53 status.
    Byrd, JC
    Shinn, CA
    Bedi, A
    Waselenko, JK
    Flinn, IW
    Diehl, LF
    Sausville, E
    Grever, MR
    BLOOD, 1997, 90 (10) : 4125 - 4125
  • [43] Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53
    Christodoulopoulos, G
    Fotouhi, N
    Krajewski, S
    Reed, JC
    AlaouiJamali, M
    Panasci, L
    CANCER LETTERS, 1997, 121 (01) : 59 - 67
  • [44] Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)
    Meacham, Philip J.
    Williams, AnnaLynn M.
    Strawderman, Myla
    Baran, Andrea M.
    Archibald, William J.
    Wallace, Danielle S.
    Tschernia, Nicholas P.
    Burack, Walter Richard
    Barr, Paul M.
    Zent, Clive S.
    LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1636 - 1644
  • [45] Characterization of microvesicles in B-Cell chronic lymphocytic leukemia (CLL): A potential mediator in CLL B cell disease progression?
    Ghosh, Asish K.
    Kay, Neil E.
    BLOOD, 2007, 110 (11) : 230A - 230A
  • [46] Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia
    Schaffner, C
    Stilgenbauer, S
    Rappold, GA
    Döhner, H
    Lichter, P
    BLOOD, 1999, 94 (02) : 748 - 753
  • [47] The ATM gene is deleted in a subgroup of B-cell chronic lymphocytic leukemia.
    Starostik, P
    Manshouri, T
    OBrien, S
    Freireich, E
    Kantarjian, H
    Lerner, S
    Keating, M
    Albitar, M
    BLOOD, 1997, 90 (10) : 396 - 396
  • [48] p53 Homolog TAp63 elicits apoptosis in Chronic Lymphocytic Leukemia (CLL) B-Cells
    Collins, Ryan
    Kaur, Prabhjot
    Danilova, Olga
    Direnzo, James
    Danilov, Alexey V.
    BLOOD, 2011, 118 (21) : 1664 - 1664
  • [49] IN-VITRO SENSITIVITY TO CAMPTOTHECINS IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA (B-CLL) WITH AND WITHOUT P53-GENE MUTATION
    COSTIN, D
    POTMESIL, M
    NEWCOMB, EW
    ELROUBY, S
    THOMAS, A
    DRYGAS, J
    MORSE, L
    SILBER, R
    BLOOD, 1993, 82 (10) : A43 - A43
  • [50] Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab
    Sebejova, Ludmila
    Borsky, Marek
    Jaskova, Zuzana
    Potesil, David
    Navrkalova, Veronika
    Malcikova, Jitka
    Sramek, Martin
    Doubek, Michael
    Loja, Tomas
    Pospisilova, Sarka
    Mayer, Jiri
    Trbusek, Martin
    EXPERIMENTAL HEMATOLOGY, 2014, 42 (10) : 867 - 874
12345